Effect of canagliflozin on insulin sensitivity in insulin-dysregulated horses as assessed by euglycemic hyperinsulinemic clamp: a randomized, placebo-controlled trial
Journal of Veterinary Internal Medicine · 01.09.2026 · 40 (5)
DOI: 10.1093/jvimsj/aalag285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 29.10.2026. Verfasst von Elin Svonni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden. Hauptthemen laut MEDLINE: Canagliflozin, Horse Diseases, Hypoglycemic Agents, Insulin Resistance. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Max Stenbeck Charitable Fund.
Abstract (Originalsprache)
Background
Insulin resistance, enhanced β-cell responsiveness, and lower insulin clearance contribute to hyperinsulinemia in horses with insulin dysregulation. Canagliflozin (CAN) reduces hyperinsulinemia in horses, but its effect on insulin sensitivity (IS) remains unclear. Hypothesis/Objectives Evaluate the effects of CAN on IS and insulin clearance using a euglycemic hyperinsulinemic clamp (EHC) and on β-cell responsiveness using a graded glucose infusion test (GGI) in insulin-dysregulated (ID) horses. Animals Twenty privately owned ID mares.
Methods
In this randomized, double-blind, placebo-controlled study, horses received CAN (0.4 mg/kg, n = 10) or placebo (PBO, n = 10) PO once daily for 4 weeks. Insulin sensitivity and insulin metabolic clearance rate (MCR) were assessed by EHC, and β-cell responsiveness by GGI.
Results
Insulin sensitivity (M/I) was lower with CAN than PBO (1.5 ± 0.2 vs 2.7 ± 0.2 [mg/kg/min × 103]/[μIU/mL]; LS mean difference,—1.3 [95% CI, -1.9 to -0.6]; P < .001), whereas insulin MCR was higher (6.5 ± 0.3 vs 5.4 ± 0.3 mL/kg/min; LS mean difference, 1.0 [95% CI, 0.3-1.8]; P = .01). Beta-cell responsiveness (ΔI vs ΔG) was 43.3% lower with CAN (20.8 [95% CI, 16.9-25.5] vs 36.7 [29.9-45.1] mIU/mmol; ratio of geometric LS means, 0.57 [95% CI, 0.42-0.76]; P < .001). Conclusions and clinical importance Beta-cell responsiveness was lower and insulin clearance higher in CAN-treated ID mares, despite apparently lower IS. Higher endogenous glucose production in CAN-treated mares might have contributed to an underestimation of IS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden.
- Department of Animal Biosciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden.
- Department of Women's and Children's Health; Centre for Health and Sustainability, Uppsala University, 751 85 Uppsala, Sweden.
ORCID-Profile: Elin Svonni, Peter Michanek, Peter Bergsten, Sanna Lindåse, Johan Bröjer
Förderung
- Max Stenbeck Charitable Fund
Zitieren
APA
Svonni, E., Michanek, P., Bergsten, P., Lindåse, S., & Bröjer, J. (2026). Effect of canagliflozin on insulin sensitivity in insulin-dysregulated horses as assessed by euglycemic hyperinsulinemic clamp: a randomized, placebo-controlled trial. Journal of Veterinary Internal Medicine, 40(5). https://doi.org/10.1093/jvimsj/aalag285
Vancouver
Svonni E, Michanek P, Bergsten P, Lindåse S, Bröjer J. Effect of canagliflozin on insulin sensitivity in insulin-dysregulated horses as assessed by euglycemic hyperinsulinemic clamp: a randomized, placebo-controlled trial. Journal of Veterinary Internal Medicine. 2026;40(5). doi:10.1093/jvimsj/aalag285
BibTeX
@article{Svonni2026,
author = {Svonni, Elin and Michanek, Peter and Bergsten, Peter and Lindåse, Sanna and Bröjer, Johan},
title = {Effect of canagliflozin on insulin sensitivity in insulin-dysregulated horses as assessed by euglycemic hyperinsulinemic clamp: a randomized, placebo-controlled trial},
journal = {Journal of Veterinary Internal Medicine},
year = {2026},
volume = {40},
number = {5},
doi = {10.1093/jvimsj/aalag285}
}
EUVIMED